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Daptomycin MICs for enterococci are typically 1- to 2-fold higher than those for Staphylococcus aureus, and there is an immi-
nent need to establish the optimal dose for appropriate treatment of enterococcal infections. We investigated the bactericidal
activity of daptomycin at various dose exposures compared to that of linezolid against vancomycin-resistant enterococcus (VRE)
in an in vitro pharmacokinetic/pharmacodynamic model utilizing simulated endocardial vegetations over 96 h. Daptomycin at
doses of 6, 8, 10, and 12 mg/kg of body weight/day and linezolid at a dose of 600 mg every 12 h were evaluated against two clinical
vancomycin-resistant Enterococcus faecium strains (EFm11499 and 09-184D1051), one of which was linezolid resistant (09-
184D1051), and one clinical vancomycin-resistant Enterococcus faecalis strain (EFs11496). Daptomycin MICs were 4, 2, and 0.5
g/ml for EFm11499, 09-184D1051, and EFs11496, respectively. Bactericidal activity, defined as a >3 log10 CFU/g reduction
from the initial colony count, was demonstrated against all three isolates with all doses of daptomycin; however, bactericidal
activity was not sustained with the daptomycin 6- and 8-mg/kg/day regimens. Linezolid was bacteriostatic against EFm11499
and displayed no appreciable activity against 09-184D1051 or EFs11496. Concentration-dependent killing was displayed with
more sustained reduction in colony count (3.58 to 6.46 and 5.89 to 6.56 log10 CFU/g) at 96 h for the simulated regimen of dapto-
mycin at doses of 10 and 12 mg/kg/day, respectively (P < 0.012). No E. faecium mutants with reduced susceptibility were recov-
ered at any dosage regimen; however, the E. faecalis strain developed reduced daptomycin susceptibility with daptomycin at 6, 8,
and 10 but not at 12 mg/kg/day. Daptomycin displayed a dose-dependent response against three VRE isolates, with high-dose
daptomycin producing sustained bactericidal activity. Further research is warranted.
Daptomycin (DAP) is a lipopeptide antibiotic with concentra-tion-dependent activity against Gram-positive bacteria that
is currently approved for the treatment of staphylococcus bacte-
remia and right-sided endocarditis at a dose of 6 mg/kg of body
weight/day (7). Daptomycin also displays in vitro activity against
almost all Enterococcus spp., including those resistant to other an-
tibiotics, such as vancomycin, linezolid (LZD), and quinupristin-
dalfopristin (3, 22, 38). Daptomycin exhibits a lower potency
against enterococci than that against staphylococci, demonstrat-
ing higher Clinical Laboratory and Standards Institute (CLSI)
breakpoints (4 g/ml versus 1 g/ml), MIC50 values (1 to 2
g/ml versus 0.25 g/ml), and MIC90 values (1 to 2 g/ml versus
0.5 g/ml) (11, 38). Based on in vivo neutropenic mice infection
models, maximum concentration (Cmax)/MIC and area under the
concentration-time curve (AUC)/MIC ratios are the best predic-
tors for efficacy of daptomycin against infections caused by both
Staphylococcus spp. and Enterococcus spp. (39) Additionally, in
vitro pharmacokinetic/pharmacodynamic (PK/PD) models have
demonstrated a clear dose-effect relationship of daptomycin with
reduction of log10 CFU/ml (9). The simulated effective dose to
achieve 80% maximal kill activity was 3 mg/kg for the two staph-
ylococcal isolates (MICs of 0.125 and 0.25 g/ml) and 6.8 mg/kg
for the two Enterococcus faecium isolates (MICs of 2 and 4 g/ml)
(9). Based on the available data, the current Food and Drug Ad-
ministration-approved dose of 6 mg/kg/day for Staphylococcus au-
reus bacteremia and right-sided infective endocarditis infections is
likely suboptimal for infections caused by most enterococcus due
to the higher MIC values and leads to the logical conclusion that
higher daptomycin doses (i.e., 6 mg/kg/day) will be required to
adequately treat these infections.
Clinical experience with daptomycin for the treatment of en-
terococcal infections is limited to several retrospective, observa-
tional studies of patients with enterococcal bacteremia (12, 14, 17,
18, 20, 21, 28, 29, 31, 32). Success rates in these series vary from
58.1% to 90% depending on the severity of illness of the included
patients and the inclusion of clinical or microbiological results in
the definition of success. Although these retrospective studies
have several limitations, they provide some clinical support that
standard doses of daptomycin (6 mg/kg) may be suboptimal for
serious enterococcal infections, such as bacteremia and endocar-
ditis. Additional data to support the use of high-dose daptomycin
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for the treatment of enterococcal infections are vital to ensuring its
appropriate use and efficacy in treating enterococcal infections
and establishing daptomycin as the preferred bactericidal regimen
for the treatment of serious enterococcal infections. A retrospec-
tive analysis of high-dose daptomycin (8 mg/kg/day) in 250 pa-
tients with both S. aureus and enterococcal infections reported
that daptomycin was safe and well-tolerated with no dose-re-
sponse relationship to changes in creatine phosphokinase (CPK)
levels (24). That and other studies suggest that the routine use of
high-dose daptomycin, ranging from 8 to 14 mg/kg/day, to treat
enterococcal infections is safe and clinically feasible (6, 13, 15, 16,
23, 24, 33). The purpose of the current study was to examine the
effects of standard and various high-dose daptomycin regimens
on both bactericidal killing and the emergence of nonsusceptibil-
ity in an in vitro model of enterococcal infection compared to the
effects of linezolid.
(This study was presented in part at the 51st Interscience Con-
ference on Antimicrobial Agents and Chemotherapy, Chicago, IL,
2011, and at the 22nd European Congress of Clinical Microbiol-
ogy and Infectious Diseases, London, United Kingdom, 2012.)
MATERIALS AND METHODS
Bacterial strains. A total of three clinical vancomycin-resistant entero-
coccus (VRE) strains were evaluated. Two clinical E. faecium strains were
evaluated (SF11499, daptomycin MIC of 4 g/ml), one of which was
linezolid resistant (09-184D1051, DAP MIC of 2 g/ml), and one clinical
Enterococcus faecalis strain (SF11496, DAP MIC of 0.5 g/ml) was utilized.
Isolates SF11499 (EFm11499) and SF11496 (EFs11496) were obtained
from blood and urine sources, respectively, from a patient at Henry Ford
Hospital in Detroit, MI. E. faecium isolate 09-184D1051 was recovered
from a patient in Houston, TX.
Antimicrobials. Daptomycin (DAP) analytical powder (Cubist Phar-
maceuticals, Inc., Lexington, MA) was provided by the manufacturer.
Linezolid (LZD) 2-g/ml solution was commercially purchased (Detroit
Receiving Hospital, Detroit, MI).
Media. Mueller-Hinton broth II (MHB II; Difco, Detroit, MI) with 25
mg/liter of calcium and 12.5 g/ml magnesium was used for susceptibility
testing and in vitro pharmacodynamic simulated endocardial vegetation
(SEV) models. Due to the dependency of daptomycin on calcium for
antimicrobial activity, supplemented MHB II (SMHB II) containing 50
g/ml of calcium was used for susceptibility testing, and that containing
75 g/ml of calcium (50 and 75 SMHB, respectively) was used for in vitro
SEV model experiments (due to binding of calcium by albumin) (25).
Colony counts were determined using brain heart infusion agar (BHA;
Difco, Detroit, MI). Nonsusceptibility was assessed with antibiotic-con-
taining MHB II plus agar (Becton, Dickinson, Sparks, MD) supplemented
to 50 mg/liter of calcium and BHA for daptomycin and linezolid, respec-
tively.
Susceptibility testing. MICs and minimum bactericidal concentra-
tions (MBCs) of daptomycin and linezolid were determined in duplicate
by broth microdilution at 5  105 CFU/ml in 50 SMHB II as specified
above, according to the CLSI guidelines (11). Etest methodology, accord-
ing to manufacturer recommendations, was used for any isolate observed
to grow on DAP- or LZD-containing agar plates (Mueller-Hinton agar
[MHA] for daptomycin, BHA for linezolid) used for screening changes in
susceptibility during model experiments.
Simulated endocardial vegetations. SEVs were prepared by mixing
0.05 ml of organism suspension (final inoculum, 108.5 CFU/g), 0.5 ml of
human cryoprecipitate antihemophilic factor from volunteer donors
(American Red Cross, Detroit, MI), and 0.025 ml of platelet suspension
(platelets mixed with normal saline, 250,000 to 500,000 platelets per clot)
in 1.5-ml siliconized Eppendorf tubes. Bovine thrombin (5,000 units/ml),
0.05 ml, was added to each tube after insertion of a sterile monofilament
line into the mixture. The resultant simulated vegetations were then re-
moved from the Eppendorf tubes with a sterile plastic needle (Becton,
Dickinson, Sparks, MD) and introduced into the model. This methodol-
ogy resulted in SEVs consisting of approximately 3 to 3.5 g/dl of albumin
and 6.8 to 7.4 g/dl of total protein (1).
In vitro PK/PD model. An in vitro PK/PD infection model consisting
of a 250-ml glass apparatus with ports, where the SEVs were suspended,
was utilized for all simulations. 75 SMHB II supplemented with 3.5 g/dl of
human albumin (Baxter, Deerfield, IL) was used as the medium. The
apparatus was prefilled with 250 ml of medium, and antibiotics were
administered as boluses over a 96-h period into the central compartment
via an injection port. The model apparatus was then placed into a 37°C
incubator for the duration of the procedure, and a magnetic stir bar was
placed in the medium for thorough mixing of the drug in the model. Fresh
medium was continuously supplied and removed from the compartment
along with the drug via a peristaltic pump (Masterflex; Cole-Parmer In-
strument Company, Chicago, IL) set to simulate the half-lives of the an-
tibiotics. Simulated regimens included daptomycin at doses of 6 (DAP6),
8 (DAP8), 10 (DAP10), and 12 (DAP12) mg/kg daily (target peaks, 93.9,
123.3, 141.1, and 183.7 g/ml, respectively; area under the concentration-
time curve from 0 to 24 h [AUC0-24], 631.8 to 1,277.4 g · h/ml; average
half-life, 8 h) (6) and linezolid (LZD) at a dose of 600 mg every 12 h (target
peak, 15.1 g/ml; average half-life, 5 h) (19, 36). All models were run in
duplicate to ensure reproducibility.
Pharmacodynamic analysis. Two SEVs were removed from each
model at 0, 4, 8, 24, 32, 48, 56, 72, and 96 h. The SEVs were homogenized
and diluted in cold saline to be plated on BHI plates. For all samples,
antimicrobial carryover was accounted for by serial dilution of the plated
samples. If the anticipated dilution was near the MIC, samples were pro-
cessed via vacuum filtration and washed through a 0.45-m filter (Pall
Corporation, Ann Arbor, MI) with normal saline to remove the antimi-
crobial agent. The limit of detection for determination of colony counts
was 1 log10 CFU/g. Plates were then incubated at 37°C for 24 h, and the
colony count was performed at the 24-h time point. The total reduction in
log10 CFU/g over 96 h was determined by plotting time-kill curves based
on the number of remaining organisms over the time period. Bactericidal
activity (99.9% kill) and bacteriostatic activity were defined as a 3 log10
CFU/g or a 3 log10 CFU/g reduction in colony count from that of the
initial inocula, respectively. Inactivity was defined as no observed reduc-
tion compared to results for the initial inocula. The time to achieve a
99.9% bacterial load reduction was determined by linear regression (if
r2  0.95) or visual inspection.
Pharmacokinetic analysis. Pharmacokinetic samples were obtained,
through the injection port of each model (duplicate samples) at 0, 0.5, 1, 2,
4, 8, 24, 32, 48, 56, 72, and 96 h for verification of target antibiotic con-
centrations. All samples were stored at 70°C until ready for analysis.
Concentrations of DAP were determined by microbioassay utilizing Mi-
crococcus luteus ATCC 9341. Briefly, blank quarter-inch disks were spot-
ted with 10 l of the standards or samples. Each standard was tested in
duplicate by placing the disk on antibiotic medium 5 plates (Becton Dick-
inson, Sparks, MD) that were preswabbed with a 0.5 McFarland suspen-
sion of the test organism. Plates were incubated for 18 to 24 h at 37°C, and
at 24 h, the zone sizes were measured using a protocol reader (Protocol;
Microbiology International, Frederick, MD). Concentrations of 200, 100,
150, and 50 g/ml were used as standards. This assay has a lower limit of
detection of 5 g/ml and demonstrates an interday coefficient of variation
percentage (CV%) of 10.9% for daptomycin (2). Concentrations of
LZD were determined using a validated high-performance liquid chroma-
tography (HPLC) assay (30). Samples were measured using a system con-
sisting of a ThermoFinnegan P4000 HPLC pump (San Jose, CA) with a
model AS1000 fixed-volume autosampler, a model UV2000 UV detector,
a Gateway Series e computer (Poway, CA), and the Chromquest HPLC
data management system. The plasma standard curve for LZD ranged
from 0.5 to 30 g/ml and demonstrated a CV% of 1.04% to 4.39% for
LZD (30). The half-life, area under the curve (AUC0-24 h), and peak con-
centration were determined by the trapezoidal method utilizing PK Ana-
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lyst software (version 1.10; MicroMath Scientific Software, Salt Lake
City, UT).
Nonsusceptibility. Development of nonsusceptibility was evaluated
at multiple time points throughout the simulation, at 24, 48, 72, and 96 h
for days 1 to 4. Samples (100 l) from each time point were plated on agar
plates (BHI for linezolid, MHA for daptomycin) containing three times
the MIC of the respective antibiotic to assess the development of resis-
tance. Plates were then examined for growth after 24 to 48 h of incubation
at 37°C. Any observed growth was tested for changes in susceptibility by
both Etest and broth microdilution.
Statistical analysis. Changes in CFU/g at 24, 48, 72, and 96 h were
compared by one-way analysis of variance with Tukey’s post hoc test. A P
value of 0.05 was considered significant. All statistical analyses were
performed using SPSS statistical software (release 20.0; SPSS, Inc., Chi-
cago, IL).
RESULTS
Organism susceptibilities to DAP are displayed in Table 1. The
two E. faecium isolates (EFm11499, 09-184D1051) and the E.
faecalis isolate (EFs11496) were susceptible to DAP, displaying
MICs of 4, 2, and 0.5 g/ml, respectively. One E. faecium isolate
(09-184D1051) was LZD resistant, with an MIC of 16 g/ml.
EFm11499 and EFs11496 were susceptible to LZD, with MICs of 2
and 1 g/ml, respectively. MBCs of DAP were 4, 8, and 4 g/ml for
09-184D1051, EFm11499, and EFs11496, respectively. MBCs of
LZD were 16 for all isolates. No change in DAP or LZD suscep-
tibility was found for either of the E. faecium isolates during the
study. In vitro changes in susceptibility at 96 h are displayed in
Table 1. Decreased susceptibility to DAP developed in EFs11496
when exposed to DAP6 and DAP8, producing a 32-fold increase in
MIC (which increased from 0.5 to 16 g/ml). In DAP10, one SEV
sample from a single model developed an increased MIC to DAP
(MIC of 8 g/ml). This organism was found stable to three over-
night passes onto antibiotic-free medium. No resistance was seen
with DAP12 or LZD.
PK parameters of simulated regimens are displayed in Table 2.
Observed pharmacokinetic parameters for LZD were within 12%
of the targeted range. The Cmax and half-life for LZD were 14.4 
0.3 g/ml and 4.4  0.28 h (targeted values, 15.1 g/ml and 5 h).
Observed PK parameters for DAP were all within 11% of the tar-
geted values. The Cmax and half-life observed were 105.1  10.5
g/ml and 7.93 h, 123.1  7.4 g/ml and 8.54 h, 144.2  4.0
g/ml and 7.87 h, and 188.7  4.9 g/ml and 8.36 h (targeted
Cmax, 93.9, 123.3, 141.1, and 183.7 g/ml; average half-life, 8 h) for
DAP6, DAP8, DAP10, and DAP12, respectively. DAP AUC24/
MIC ratios ranged from 235 to 4,367 (Table 2) and varied depend-
ing on the organism MIC.
The in vitro activity of the simulated regimens is displayed in
Table 1. LZD was bacteriostatic against EFm11499 and EFs11496
(Fig. 1) and displayed no appreciable activity against LZD-resis-
tant 09-184D1051. All DAP regimens demonstrated bactericidal
activity against LZD-resistant 09-184D1051. DAP6 and DAP8 dis-
played improved killing over that of LZD against 09-184D1051,
EFm11499, and EFs11496, with times to a 99.9% kill (T99) of 32, 4,
and 24 h for DAP6 and 4, 8, and 24 h for DAP8, respectively.
However, both DAP6 and DAP8 failed to maintain bactericidal
activity at 96 h in all three strains. DAP6 exhibited the least effect
with the most regrowth, patterned closely by DAP8. In contrast,
the rapid bactericidal activity of DAP10 and DAP12 was sustained
to 96 h. These two regimens were similar except against
EFm11499, which had the highest MIC for daptomycin. Against
09-184D1051, EFm11499, and EFs11496, DAP10 and DAP12 dis-
played rapid and sustained bactericidal activity (T99S) at 96 h, with
a T99S of 4 h for all isolates for DAP10 and a T99S of 4, 8, and 4 h,
respectively, for DAP12. These regimens were significantly more










MIC (g/ml)e24 h 96 h
09-184D1051a 2 DAP6 32 h NA 1.72  0.10† 2.32  0.05†
DAP8 4 h NA 6  0.32*† 2.87  0.37†
DAP10 4 h 4 h 5.3  0.39*† 4.71  0.71*†
DAP12 4 h 4 h 6.4  0.21*† 6.04  1.46*†
LZD NA NA 1.81  0.09 2.33  0.03
EFm11499a 4 DAP6 4 h NA 2.31  0.85† 0.01  0.19
DAP8 8 h NA 3.34  0.95† 1.17  0.16
DAP10 4 h 4 h 4.46  0.26*† 3.58  1.45*†
DAP12 8 h 8 h 5.01  0.18*† 6.56  0.43*†
LZD NA NA 0.83  0.27 1.08  0.89
EFs11496 0.5 DAP6 24 h NA 4.18  1.27† 0.65  0.37 8
DAP8 24 h NA 4.5  0.7† 2.27  1.07† 16
DAP10 4 h 4 h 5.61  0.18† 6.46  1.19*† 8
DAP12 4 h 4 h 6.87  0.12*† 5.89  0.11*†
LZD NA NA 0.24  0.07† 0.28  0.25
a No resistant mutants recovered from DAP or LZD simulated regimens.
b NA, not achieved; T99, time to achieve a 99.9% colony reduction.
c NA, not achieved; T99S, time to achieve a 99.9% colony reduction that was sustained to 96 h.
d T0, time zero; *, P value of 0.05 for improved killing compared with that for the DAP 6 regimen; †, P value of 0.05 for improved killing compared with that for the LZD
regimen.
e Recovered nonsusceptible mutants (performed via BMD).
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efficacious at decreasing the log10 CFU/g than DAP6, DAP8, and
LZD at 72 and 96 h against 09-184D1051 (P  0.008), at 96 h
against EFm11499 (P  0.012), and at 48 to 96 h against EFs11496
(P  0.011). DAP10 had an overall kill count reduction of 4.46 to
5.61 log10 CFU/g at 24 h and 3.58 to 6.46 log10 CFU/g at 96 h.
DAP12 had an overall kill count reduction of 5.01 to 6.87 log10
CFU/g at 24 h and 5.89 to 6.56 log10 CFU/g at 96 h. For EFm11499,
DAP12 demonstrated significantly more killing than DAP10 at 72
and 96 h (P  0.001), but activity was not significantly improved
over that of DAP10 for 09-184D1051 or EFs11496 at 96 h.
DISCUSSION
Enterococcal infections are difficult to treat, especially in immu-
nocompromised hosts and in those with deep-seated, high-inoc-
ulum infections, such as device-related infections and infective
endocarditis (5, 26, 34, 37). Few therapeutic options are available,
and bactericidal agents or combination therapy have been pre-
ferred for life-threatening infections (23). Linezolid demonstrates
bacteriostatic activity, and prolonged therapy can result in throm-
bocytopenia. Quinupristin-dalfopristin is a last-line effort, being
poorly tolerated with substantial toxicities. Daptomycin is a con-
centration-dependent cyclic lipopeptide with demonstrated in
vitro bactericidal activity against enterococci. Daptomycin MIC
values are higher for enterococci than for S. aureus (11, 38). Max-
imum effect (Emax) models suggest that increased doses (7.9
mg/kg/day) may be needed to surmount this; however, a paucity
of data exist evaluating escalating doses for activity against entero-
cocci (9). Daptomycin resistance is still relatively rare; however,
clinical cases are emerging for both E. faecium and E. faecalis,
notably in patients with more complicated conditions (e.g., osteo-
myelitis, endocarditis, device-related infections, biofilm) (5, 26,
34). A recent review of daptomycin nonsusceptibility in entero-
cocci from 23 studies from 2003 to 2010 reported an overall prev-
alence rate of 0.6% (23). The majority of the strains reported were
vancomycin resistant (93.3%), with 88% being reported as E. fae-
cium. Of interest, the most common dosage of daptomycin asso-
ciated with resistance was 6 mg/kg/day. Although the optimal dos-
age of daptomycin for treatment of enterococcal infections is
unknown, the authors suggested that dosages greater than what is
currently recommended (4 to 6 mg/kg/day) may be required (23).
The exact mechanism of enterococcal resistance to daptomycin is
not fully elucidated. Similar to S. aureus resistance, enterococcal
resistance is thought to result from several factors, including al-
tered cell membrane composition and increased positive surface
charge, altered ability of daptomycin to depolarize the cell, and
cell wall thickening associated with genetic mutations; however,
the affected genes appear to be different from those observed for S.
aureus resistance (4, 23, 35, 40). Insights into the mechanism of
daptomycin resistance in enterococci have recently been provided
(4, 35). Whole-genome sequencing of a clinical strain pair of dap-
tomycin-susceptible and -resistant E. faecalis obtained from the
blood of a patient before and after daptomycin therapy, respec-
tively, indicated that changes in two genes were necessary and
sufficient for daptomycin resistance: (i) the liaF gene, which en-
codes a member of a three-component regulator (LiaFRS) that is
likely to be involved in the stress-sensing response to cell envelope
antibiotics and antimicrobial peptides, and (ii) the glycerophos-
phoryl diester phosphodiesterase gene, predicted to be involved in
phospholipid metabolism. The genetic changes were associated
with important ultrastructural alterations of the cell envelope and
TABLE 2 Pharmacokinetic parameters of daptomycin and linezolid achieved in the PK/PD modela
Drug, dosage, and strain
Cmax (g/ml)
(target value) Half-life (h) AUC0-24 (g · h/ml) AUC24/MIC
c




















a Cmax, maximum concentration; AUC0-24; area under the concentration-time curve from 0 to 24 h. Results are expressed as means  standard deviations.
b q12h, every 12 h.
c Varied based on organism MIC.
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affected the ability of daptomycin to depolarize and permeabilize
the cell membrane (4). In vitro selection of E. faecalis V583 in high
concentrations of daptomycin resulted in changes in seven differ-
ent genes. The predominant alteration was found in a gene encod-
ing a putative cardiolipin synthase found in all resistant mutants
observed. Cloning of the mutated allele of the cardiolipin synthase
gene in a multicopy plasmid resulted in reduced susceptibility to
daptomycin of V583, supporting the role of phospholipid en-
zymes in the resistance mechanism (35). Of note, changes in both
the putative LiaFRS system and cardiolipin synthase have been
FIG 1 Activities of LZD, DAP6, DAP8, DAP10, and DAP12 against 09-184D1051 (A), EFm11499 (B), and EFs11496 (C).
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observed with unrelated daptomycin-resistant clinical isolates of
E. faecium and other E. faecalis isolates (4, 35).
The present study demonstrates a dose-response curve utiliz-
ing escalating doses of daptomycin compared with standard-dose
linezolid against clinical vancomycin-resistant E. faecium and E.
faecalis strains. In this study, we found that DAP6, as predicted,
did not maintain bactericidal activity against E. faecium and E.
faecalis, and regrowth was noted at 96 h. DAP10 and DAP12 dis-
played the most significant and sustained killing over the 96-h
duration. We noted a concentration-dependent effect; as doses
were escalated, bactericidal activity was prolonged. Overall, there
was not a profound difference between results for the isolates.
Although the overall doses and AUC requirements for effective
and sustained activity were similar for E. faecalis and E. faecium,
the AUC24/MIC ratios varied considerably based on the MIC
(range, 0.5 to 4 g/ml).
The PD parameter for daptomycin that best predicts outcome
for S. aureus is the AUC24/MIC ratio (8, 27). Louie et al. reported
an 80% maximal kill for S. aureus, and the AUC24/MIC ratio that
correlated with bactericidal activity for the daptomycin dose of 6
mg/kg in animals was 245 to 516, depending on the organism MIC
(27). Cha et al. reported an AUC24/MIC ratio of 502 and 705 for
daptomycin doses of 6 and 8 mg/kg daily, respectively, for vanco-
mycin-resistant E. faecium (10). In the current investigation, the
AUC0-24 was proportional to the dose administered (6 to 12 mg/
kg/day), and the corresponding AUC24/MIC ratio ranged from
235 to 4,367 and varied according to the organism MIC. The min-
imum AUC0-24 needed for sustained bactericidal activity was
1,540, and the corresponding AUC24/MIC ratio was 214 to 1,715,
dependent upon the MIC (DAP MIC of 0.5 to 4 g/ml).
Limitations of this study include the utilization of only three
isolates for testing; therefore, the results may not be representative
of those for all daptomycin and enterococcal interactions. A lon-
ger duration of exposure (e.g., 96 h) is needed to verify that
killing is sustained and that there is suppression of resistance. In
addition, a specific dose breakpoint should be pursued to deter-
mine the optimal AUC24/MIC exposure for each Enterococcus sp.
best correlating with sustained bactericidal killing and suppres-
sion of emergence of resistance.
In conclusion, daptomycin doses of 10 mg/kg per day may be
necessary to treat high-inoculum vancomycin-resistant E. faecium
and E. faecalis infections, such as those found in patients with
infective endocarditis.
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